Genmab — August 2020
-
Det går godt nok noget op og ned i dag...godt man ikke lider af søsyge...;-)
-
Jeg tror Vitus mener fra toppen i dag...
-
Enig Solsen...Genmab har været outstandig...lige bortset fra det "lille" dip i marts.:-)
-
Man skulle have købt ALT den gang...ryddet alle sparebøsser og lignende....meeen turde ikke..;-)
-
Vi arbejder pt. på indstillinger i debatten. Beklager udfald.
-
“Approximately half of patients with light-chain amyloidosis have some degree of heart involvement and are sensitive to volume overload.Since daratumumab had to be given as a prolonged intravenous infusion with a significant amount of fluid volume, one of our main concerns had been aggravation of congestive heart failure in these patients.
-
The subcutaneous administration is a significant advance that minimizes the chances of fluid overload and exacerbation of congestive heart failure. Additionally, the shorter infusion time may improve patients’ quality of life.” https://ascopost.com/issues/august-25-2020/epov-taimur-sher/
-
Bryan Garnier yesterday:
GENMAB NEUTRAL | DKK2200 vs. DKK2150 Ofatumumab (now Kesimpta) approved in the US
1st subcutaneous anti-CD20 therapy to be approved for RMS
Three key characteristics resulting in a differentiated profile
Treatment practices are shifting towards high efficacy therapies
FV increased to DKK2200, Neutral rating confirmed -
Thanks E L .
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind